-

Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries.

Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Share

On June 11, 2025, Simulations Plus announced preliminary third-quarter fiscal 2025 revenue and updated its full-year fiscal 2025 revenue outlook, citing market uncertainties as headwinds. On this news, the Company’s stock fell over 24%, from $26.44 to $20.05 per share.

Then, on July 14, 2025, Simulations Plus reported disappointing third-quarter fiscal 2025 results, including a net loss of $67.3 million and a $77.2 million non-cash impairment charge. The following day, the Company disclosed that it had dismissed its auditor, Grant Thornton LLP. Simulations Plus stated that certain matters involving segment reporting, reporting-unit determinations, and internal control over financial reporting could not be finalized in time for its Form 10-Q. On this news, shares fell nearly 26%, from $17.47 to $12.97 per share.

What Now: If you lost money in your investment of Simulation Plus, Inc., contact Robbins LLP for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Simulation Plus, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:SLP
Release Versions
English
$Cashtags
$SLP
Hashtags
#Inc
#Plus
#Simulation
#classaction
#classactionlawyer
#investorfraud
#investorrights
#leadplaintiff
#shareholderrights
#stockdrop
#stockfraud
#stockholderrights

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
Robbins LLP
Robbins LLP
More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.For more information, submit a form, email attorney Aaron D...
Back to Newsroom